sunbet

sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Á¬Ã¦ËÑË÷
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Á¬Ã¦ËÑË÷
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
»ùÒòÐÞÊÎÅÁ½ðÉ­²¡¶¯ÎïÄ£×Ó
Ä¿½ñλÖãºÊ×Ò³ > ÈËÀ༲²¡¶¯ÎïÄ£×ÓĿ¼ > Éñ¾­ÏµÍ³Ä£×Ó > »ùÒòÐÞÊÎÅÁ½ðÉ­²¡¶¯ÎïÄ£×Ó

ǰÑÔ

Ó¦ÓûùÒò¹¤³ÌµÈʵÑéÊÖÒÕ¶Ô¶¯Îï»ùÒò×é¾ÙÐÐÓÐÄ¿µÄµÄÒÅ´«ÐÞÊΣ¬ÕâÖÖ±»ÐÞÊÎˢеĻùÒò¿ÉÎȹÌÒÅ´«¸ø×ÓÅ®¶¯Îï¡£»ùÒòÇóýºÍת»ùÒòÊÇ»ùÒòÐÞÊÎÅÁ½ðÉ­²¡¶¯ÎïÄ£×ÓµÄÖ÷ÒªÖÆ×÷ÒªÁì¡£

²¿·ÖÔìÄ£ÒªÁì

ʹÓö¯Î´óÊó

¡¾ÔìÄ£»úÖÆ¡¿£º

1. DJ-1ÊÇÒ»ÖÖÖ÷ÒªµÄÅÁ½ðÉ­²¡Ïà¹ØÖ²¡»ùÒò£¬DJ-1»ùÒòÇóýСÊó»òDJ-1±í´ïϵ÷µÄDAÄÜϸ°û¶ÔÑõ»¯Ó¦¼¤µÄÃô¸ÐÐÔÔöÌí£¬Ï¸°û¿¹Ñõ»¯Ó¦¼¤ÄÜÁ¦½µµÍ¼°ÏìÓ¦ÐźÅͨ·±¬·¢¸Ä±ä£¬ÖÂʹÉñ¾­ÔªµòÍö¼ÓËÙ£¬´Ó¶ø¿ÉÄÜÖÆ×÷³öÅÁ½ðÉ­²¡»ùÒòÐÞÊζ¯ÎïÄ£×Ó¡£

2. Ô­ºËÏÔ΢עÉä·¨ÊÇÏÖÔÚÖÆ×÷ת»ùÒò¶¯Îï×î³£ÓõÄÒªÁì¡£½«¹¹½¨ºÃµÄa-synuclein»ùÒòÖ±½Ó×¢Éäµ½Êܾ«ÂѵÄÐÛÔ­ºËÖУ¬È»ºó½«Ð¯´øÍâÔ´»ùÒòµÄÊܾ«ÂÑÒÆÖ²µ½Í¬Æ·Ïµ¼ÙÔÐÊÜÌåµÄÊäÂѹÜÖУ¬¿É»ña-synucleinת»ùÒòСÊ󣬷¢Ã÷¸ÃСÊóLewyСÌåÐγɼÓËÙ¡¢Éñ¾­ÔªµòÍöÔöÌí¡£

¡¾Ä£×ÓÌØµã¡¿£º

×÷ΪÒÅ´«Ò׸ÐÐÔÊܵ½¶à»ùÒòÁªÏàÖúÓõļ²²¡£¬Èκμòµ¥»ùÒòÐÞÊÎÒòËØÔÚÅÁ½ðÉ­²¡Ö²¡Öж¼»áÓÐÒ»¶¨×÷Ó㬵«¶¼²»ÆðÖ÷Òª×÷Óûò¾öÒéÐÔ×÷Óá£Òò´Ë£¬Í¨¹ýÏÖÓеĻùÒòÐÞÊÎ֪ʶºÍÊÖÒÕ£¬ÖÆ×÷µÄÅÁ½ðÉ­²¡¶¯ÎïÄ£×Ó¶¼ÓÐȱÏÝ£¬ÌåÏÖ³ö¼òµ¥µÄÉñ¾­»¯Ñ§ÔÓÂÒÄ£ËÆÐÔ»òÉñ¾­²¡Àíת±äÄ£ËÆÐÔ£¬Æä±íÐÍÌØµã£¨ÌØÊâÊÇÏ¸Î¢ÌØÕ÷£©ÓëÅÁ½ðÉ­²¡»¼Õß¶¼Óнϴó²î±ð¡£

¡¾Ä£×ӵįÀ¹ÀºÍÓ¦Óá¿£º

̽Ë÷ÖеÄÅÁ½ðÉ­²¡»ùÒòÐÞÊζ¯ÎïÄ£×ÓÒ»¶¨ÓÐÆäÁÉÀ«µÄÓ¦ÓÃÔ¶¾°£¬µ«Í¬Ê±ÉдæÐí¶àÎÊÌâÓдýսʤ¡£Òò´Ë£¬Ïֽ׶λùÒòÐÞÊζ¯ÎïÄ£×ÓµÄÓ¦Ó㬻¹ÔÝʱֻͣÁôÔÚÖ²¡»úÖÆÑо¿¡¢Éñ¾­Ôª±£»¤²½·¥É¸Ñ¡µÈÑо¿ÉÏ¡£

 

 

²Î¿¼ÎÄÏ×£º

1.³ÂÉúµÜ£®ÅÁ½ðÉ­²¡£®±±¾©£ºÈËÃñÎÀÉú³öÊéÉ磬2006

2.Engeln M, Ahmed SH, Vouillac C, el al. Reinforcing properties of Praroipexole in normal and parkinsooian rats.Neurobiol Dis, 2012, 49C: 79-86

3.Hoehn MM, Yahr MD. Parkinsonism:onset, progression and mortality. 1967. Neurology,2001,57(10 Suppl 3): S11-26

4.KitamuraY,Shimohama S,Akaike A,et al.The parkinsonian models: invertebrates to mammals. Jpn J Phannacol, 2000, 84 (3):237-243

5.Luquin MR. Experimental models of Parkinson disease. Rev Neurol, 2000, 31 (1):60-66

6.Marti M,Rodi D,Li Q,et al. Nociceptin/orphanin FQ receploT agonists allenuate L-DOPA-induced dyskinesias. J Neurosci,2012,32(46): 16106-16119

7.Meissner W, Hill MP, Tison F, et al. Neuroprotective strategies for Parkinson's disease: Conceptual limits of animal models and clinical trials. Trends Pharmacol Sci, 2004, 25 (5):249-253

8.Mokry J. Experimental models and behavioural tests used in the study of Parkinson's disease. Physiol Res,1995, 44 (3):143-150

9.Parkinson J. An essay on the shaking palsy. London: herwwod, Nelly and Jones, 1817

10.Tolwani RJ, Jakowec MW, Petzinger GM, et al. Experimental models of Parkinson's disease: insights from many models. Lab Anim Sci, 1999,49 (4):363-371

 

sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Ä£×ÓĿ¼
Ä¿½ñλÖãºÊ×Ò³ > ÈËÀ༲²¡¶¯ÎïÄ£×ÓĿ¼ > Éñ¾­ÏµÍ³Ä£×Ó > »ùÒòÐÞÊÎÅÁ½ðÉ­²¡¶¯ÎïÄ£×Ó
»ùÒòÐÞÊÎÅÁ½ðÉ­²¡¶¯ÎïÄ£×Ó

ǰÑÔ

Ó¦ÓûùÒò¹¤³ÌµÈʵÑéÊÖÒÕ¶Ô¶¯Îï»ùÒò×é¾ÙÐÐÓÐÄ¿µÄµÄÒÅ´«ÐÞÊΣ¬ÕâÖÖ±»ÐÞÊÎˢеĻùÒò¿ÉÎȹÌÒÅ´«¸ø×ÓÅ®¶¯Îï¡£»ùÒòÇóýºÍת»ùÒòÊÇ»ùÒòÐÞÊÎÅÁ½ðÉ­²¡¶¯ÎïÄ£×ÓµÄÖ÷ÒªÖÆ×÷ÒªÁì¡£

²¿·ÖÔìÄ£ÒªÁì

ʹÓö¯Î´óÊó

¡¾ÔìÄ£»úÖÆ¡¿£º

1. DJ-1ÊÇÒ»ÖÖÖ÷ÒªµÄÅÁ½ðÉ­²¡Ïà¹ØÖ²¡»ùÒò£¬DJ-1»ùÒòÇóýСÊó»òDJ-1±í´ïϵ÷µÄDAÄÜϸ°û¶ÔÑõ»¯Ó¦¼¤µÄÃô¸ÐÐÔÔöÌí£¬Ï¸°û¿¹Ñõ»¯Ó¦¼¤ÄÜÁ¦½µµÍ¼°ÏìÓ¦ÐźÅͨ·±¬·¢¸Ä±ä£¬ÖÂʹÉñ¾­ÔªµòÍö¼ÓËÙ£¬´Ó¶ø¿ÉÄÜÖÆ×÷³öÅÁ½ðÉ­²¡»ùÒòÐÞÊζ¯ÎïÄ£×Ó¡£

2. Ô­ºËÏÔ΢עÉä·¨ÊÇÏÖÔÚÖÆ×÷ת»ùÒò¶¯Îï×î³£ÓõÄÒªÁì¡£½«¹¹½¨ºÃµÄa-synuclein»ùÒòÖ±½Ó×¢Éäµ½Êܾ«ÂѵÄÐÛÔ­ºËÖУ¬È»ºó½«Ð¯´øÍâÔ´»ùÒòµÄÊܾ«ÂÑÒÆÖ²µ½Í¬Æ·Ïµ¼ÙÔÐÊÜÌåµÄÊäÂѹÜÖУ¬¿É»ña-synucleinת»ùÒòСÊ󣬷¢Ã÷¸ÃСÊóLewyСÌåÐγɼÓËÙ¡¢Éñ¾­ÔªµòÍöÔöÌí¡£

¡¾Ä£×ÓÌØµã¡¿£º

×÷ΪÒÅ´«Ò׸ÐÐÔÊܵ½¶à»ùÒòÁªÏàÖúÓõļ²²¡£¬Èκμòµ¥»ùÒòÐÞÊÎÒòËØÔÚÅÁ½ðÉ­²¡Ö²¡Öж¼»áÓÐÒ»¶¨×÷Ó㬵«¶¼²»ÆðÖ÷Òª×÷Óûò¾öÒéÐÔ×÷Óá£Òò´Ë£¬Í¨¹ýÏÖÓеĻùÒòÐÞÊÎ֪ʶºÍÊÖÒÕ£¬ÖÆ×÷µÄÅÁ½ðÉ­²¡¶¯ÎïÄ£×Ó¶¼ÓÐȱÏÝ£¬ÌåÏÖ³ö¼òµ¥µÄÉñ¾­»¯Ñ§ÔÓÂÒÄ£ËÆÐÔ»òÉñ¾­²¡Àíת±äÄ£ËÆÐÔ£¬Æä±íÐÍÌØµã£¨ÌØÊâÊÇÏ¸Î¢ÌØÕ÷£©ÓëÅÁ½ðÉ­²¡»¼Õß¶¼Óнϴó²î±ð¡£

¡¾Ä£×ӵįÀ¹ÀºÍÓ¦Óá¿£º

̽Ë÷ÖеÄÅÁ½ðÉ­²¡»ùÒòÐÞÊζ¯ÎïÄ£×ÓÒ»¶¨ÓÐÆäÁÉÀ«µÄÓ¦ÓÃÔ¶¾°£¬µ«Í¬Ê±ÉдæÐí¶àÎÊÌâÓдýսʤ¡£Òò´Ë£¬Ïֽ׶λùÒòÐÞÊζ¯ÎïÄ£×ÓµÄÓ¦Ó㬻¹ÔÝʱֻͣÁôÔÚÖ²¡»úÖÆÑо¿¡¢Éñ¾­Ôª±£»¤²½·¥É¸Ñ¡µÈÑо¿ÉÏ¡£

 

 

²Î¿¼ÎÄÏ×£º

1.³ÂÉúµÜ£®ÅÁ½ðÉ­²¡£®±±¾©£ºÈËÃñÎÀÉú³öÊéÉ磬2006

2.Engeln M, Ahmed SH, Vouillac C, el al. Reinforcing properties of Praroipexole in normal and parkinsooian rats.Neurobiol Dis, 2012, 49C: 79-86

3.Hoehn MM, Yahr MD. Parkinsonism:onset, progression and mortality. 1967. Neurology,2001,57(10 Suppl 3): S11-26

4.KitamuraY,Shimohama S,Akaike A,et al.The parkinsonian models: invertebrates to mammals. Jpn J Phannacol, 2000, 84 (3):237-243

5.Luquin MR. Experimental models of Parkinson disease. Rev Neurol, 2000, 31 (1):60-66

6.Marti M,Rodi D,Li Q,et al. Nociceptin/orphanin FQ receploT agonists allenuate L-DOPA-induced dyskinesias. J Neurosci,2012,32(46): 16106-16119

7.Meissner W, Hill MP, Tison F, et al. Neuroprotective strategies for Parkinson's disease: Conceptual limits of animal models and clinical trials. Trends Pharmacol Sci, 2004, 25 (5):249-253

8.Mokry J. Experimental models and behavioural tests used in the study of Parkinson's disease. Physiol Res,1995, 44 (3):143-150

9.Parkinson J. An essay on the shaking palsy. London: herwwod, Nelly and Jones, 1817

10.Tolwani RJ, Jakowec MW, Petzinger GM, et al. Experimental models of Parkinson's disease: insights from many models. Lab Anim Sci, 1999,49 (4):363-371

 

¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿